| Name | Title | Contact Details |
|---|
Gfk Market Measures is a East Hanover, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedData is a leading national provider of technology-enabled healthcare services designed to improve financial outcomes for hospitals by enhancing the patient experience and expanding their access to healthcare. The MedData suite of solutions includes a range of patient access & communications, revenue cycle management, and consulting & analytics services, including full service billing & coding, patient balances, eligibility & disability, third party liability and other complex A/R services, and mobile-first engagement and communication software for patients and providers. MedData has built this national presence by becoming experts at the state level. To date, we have handled billing for more than 200 million patients at our growing network of more than 2,000 hospital sites nationwide. For more than 36 years, MedData has solidified its leadership position by providing innovative solutions to the medical community and serving millions of patients across numerous medical specialties.
Deborah Heart and Lung Center was established in 1922 as a tuberculosis sanitarium and pulmonary center. Legend has it that Deborah's rural Burlington County location was the key to recovery because of its therapeutic Jersey pine barren air.
IEHP, Inland Empire Health Plan, is one of the top 10 largest Medicaid health plans and the largest not-for-profit Medicare-Medicaid plan in the country. With a network of more than 7,300 providers and 2,500 employees, IEHP serves over 1.4 million residents in Riverside and San Bernardino counties who are enrolled in Medicaid or Cal MediConnect Plan (Medicare-Medicaid Plan). Through a dynamic partnership with Providers and community, award-winning service and innovative products, IEHP is fully committed to advocating for our Members and providing them with quality, accessible and wellness-based health care services.
Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.